Company DNA profile
NanoSomiX, Inc.
Trading as NanoSomiX
NanoSomiX, Inc. develops blood-based analytic technologies using brain-derived EVs, to support neurologic research and clinical applications.
- Ref.
- FG-0064
- Delivered
- 30 Sep 2026
- Profile type
- Standard profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Aliso Viejo, United States
Profile completion rate 24 fields completed out of a total of 119
Every company is unique. Some organizations publish extensive information about their activities, while others maintain a limited public footprint. In addition, certain profile sections may not be relevant to a specific company. As a result, a 100% profile completion rate is neither expected nor required.
- 1 Core identity, 27% completed
- 2 Contact & location, 63% completed
- 3 Business activity, 42% completed
- 4 Corporate structure, 0% completed
- 5 Executive leadership, 38% completed
- 6 Financial profile, 0% completed
- 7 Ecosystem & strategy, 16% completed
- 8 Human capital, 0% completed
- 9 Innovation & R&D, 33% completed
- 10 Business model, 40% completed
- 11 Fundraising, 0% completed
- 12 Valuation, 0% completed
Every field the Company DNA defines counts once: 119 in total. A list counts as one field, whatever its length. The rate is the share of fields that contain data. Profile richness and credit consumption
Evidence Foundation70 citations · 30 domains
| Metric | Value |
|---|---|
| Evidence Citations | 70 |
| Unique Articles (URLs) | 47 |
| Source Domains | 30 |
| Coverage Period | Feb 2018 – Sep 2026 |
| Community Recognition | n/a |
| Evidence Strength Index | n/a |
Evidence Strength Index = 0.35 × citation score + 0.25 × diversity score + 0.25 × recognition score + 0.15 × freshness score. Citation and diversity scores reach 100 at 200 citations and 50 domains (log scale); freshness is judged on the newest source at the delivery date.
- 1.1Company name
- NanoSomiX, Inc.
- 1.2Commercial name
- NanoSomiX
- 1.6Legal form
- Inc.
2.1Headquarters address
- 2.1.2City
- Aliso Viejo
- 2.1.3State / province
- California
- 2.1.5Country code
- US
- 2.2Country
- United States
- 2.4Contact email
- Liz@dowlingdennis.net
- 3.1Sector
- Healthcare
- 3.2Industry
- Biotechnology
- 3.3Business description
- NanoSomiX, Inc. develops blood-based analytic technologies using brain-derived EVs, to support neurologic research and clinical applications.
- 3.4Products & services
- blood-based analytic technologies, extracellular vesicle-based immunoassays, exosome research products, isolation platforms, purification tools, analysis kits
3.7Industrial footprint
- 3.7.3Key locations
- Aliso Viejo, California
5.1CEO
5.3Other executives 1
| Evidence | ||||
|---|---|---|---|---|
| Dr. Dennis Van Epps | Vice President of Scientific Affairs | 2026 | High |
- 7.2Company strategy
- staying at the forefront of technological advancements in exosome research
- 7.3Key competitors
- Aethlon Medical, Inc., Capricor Therapeutics, Inc., System Biosciences, Inc, Exosome Diagnostics, Inc, Thermo Fisher Scientific, Inc.
7.6Partners 1
| Evidence | ||
|---|---|---|
| Beckman Coulter Diagnostics | collaboration |
9.2Patents 1
| Evidence | |||||
|---|---|---|---|---|---|
| blood-based nervous system derived exosome isolation and the use of biomarkers applicable to detecting and assessing neurologic disorders | 22 May 2018 | US | Granted | blood-based nervous system derived exosome isolation and the use of biomarkers applicable to detecting and assessing neurologic disorders including Alzheimer's disease and traumatic brain injury |
9.4Research publications 1
| Evidence | |||
|---|---|---|---|
| Circulating oligodendrocyte-derived extracellular vesicle surface markers in athletes exposed to repetitive head impacts: an exploratory study | 24 Sep 2026 | Frontiers in |
- 9.6Tech stack
- high-throughput testing systems, EV-based immunoassay platforms
10.1Revenue model types 1
- B2B
10.4Target customer segments 4
- Research
- Clinical
- diagnostic application
- therapeutic application
No data was found for these items. They are hidden from the chapters above; numbering gaps mark where they belong.
1Core identity
2Contact & location
3Business activity
4Corporate structure
- 4Entire chapter11 items
5Executive leadership
6Financial profile
- 6Entire chapter17 items
7Ecosystem & strategy
8Human capital
- 8Entire chapter4 items
11Fundraising
- 11Entire chapter4 items
12Valuation
- 12Entire chapter11 items